Lung Cancer

Early-Stage EGFRm NSCLC

Tina Cascone, MD, PhD
Updates in Small Cell Lung Cancer

Jacob Sands, MD
Importance of NGS testing for STK11 and KEAP1 mutation and impact on treatment selection

Charu Aggarwal, MD, MPH, Biagio Ricciuti, MD, PhD
Early Stage NSCLC – EGFR Mutant NSCLC

Charu Aggarwal, MD, MPH
Advances in The Management of Early-Stage EGFRm NSCLC

Charu Aggarwal, MD, MPH
The Evolving Approach to Management of Stage IV EGFRm NSCLC

Charu Aggarwal, MD, MPH
Advances in the Treatment of Small-Cell Lung Cancer

David R. Spigel, MD, FASCO
Multidisciplinary Lung Cancer Tumor Board: Management of Surgically Resected Early-Stage EGFRm NSCLC

Charu Aggarwal, MD, MPH; Tina Cascone, MD, PhD
Treatment of NSCLC in Special Populations – PDL1 negative, STK11/KEAP

Charu Aggarwal, MD, MPH
Multidisciplinary Lung Cancer Tumor Board: Management of Early Stage EGFRm NSCLC

Charu Aggarwal, MD, MPH; Brendon Stiles, MD
Multidisciplinary Lung Cancer Tumor Board: Focus on SCLC

Jacob Sands, MD; Puneeth Iyengar, MD, PhD; Charu Aggarwal, MD, MPH; Brendon Stiles, MD
The Impact of NGS Testing on Treatment Selection in Non-Oncogene Addicted Stage IV NSCLC

Charu Aggarwal, MD, MPH